Physician profile
Mark A Ringle
NPI 1497700678
$1,369.21
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $653 · 2021: $540 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.47 | 2020-2022 | |
| Lilly USA, LLC | $170.75 | 2020-2022 | |
| Amgen INC. | $146.02 | 2020-2022 | |
| Allergan, INC. | $124.95 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $110.17 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.55 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $86.58 | 2020-2021 | |
| Pfizer INC. | $86.56 | 2020-2021 | |
| Abbvie INC. | $67.14 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.35 | 2021 | |
| Antares Pharma, INC. | $50.80 | 2020-2021 | |
| Daiichi Sankyo INC. | $32.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.80 | 2020-2021 | |
| Amarin Pharma, INC. | $30.51 | 2020 | |
| Esperion Therapeutics, INC. | $20.83 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $15.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2020 | |
| Gilead Sciences, INC. | $14.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ringle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.